PMID- 32213108
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210507
IS  - 1942-0870 (Electronic)
IS  - 1942-0862 (Print)
IS  - 1942-0862 (Linking)
VI  - 12
IP  - 1
DP  - 2020 Jan-Dec
TI  - Potent neutralizing monoclonal antibodies against Ebola virus isolated from 
      vaccinated donors.
PG  - 1742457
LID - 10.1080/19420862.2020.1742457 [doi]
LID - 1742457
AB  - Ebola virus (EBOV) can cause severe hemorrhagic fever in humans, and no approved 
      treatment is currently available. Although several antibodies have achieved good 
      protection in animal models, the potential emerging isolates of ebolavirus and 
      the unknown effects of experimental antibodies in humans underscore the need to 
      develop additional antibodies to address the threat of Ebola. Here, we isolated a 
      series of memory B cell-derived monoclonal antibodies from healthy Chinese adults 
      vaccinated with Ad5-EBOV. These antibodies were encoded by diverse germline genes 
      and had high levels of somatic hypermutation. Most antibodies were cross-reactive 
      and could bind at least two ebolavirus glycoproteins (GPs). Seven neutralizing 
      antibodies were identified using HIV-EBOV GP-Luc pseudovirus, and they 
      effectively neutralized authentic EBOV. In particular, monoclonal antibody 2G1 
      exhibited potent cross-neutralization against HIV-EBOV/SUDV/BDBV GP-Luc bearing 
      different ebolavirus GPs. We used truncated GPs, competition assays, and software 
      prediction to analyze seven neutralizing antibodies, which bound four different 
      epitopes on GP. Importantly, three of these antibodies provided complete 
      protection in mice when administered one day post-infection. Our study expands 
      the list of candidate antibodies and the options for successfully treating 
      ebolavirus infection.
FAU - Fan, Pengfei
AU  - Fan P
AUID- ORCID: 0000-0002-7212-231X
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Chi, Xiangyang
AU  - Chi X
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Liu, Guodong
AU  - Liu G
AD  - Special Pathogens Program, National Microbiology Laboratory, Public Health Agency 
      of Canada, Winnipeg, Canada.
FAU - Zhang, Guanying
AU  - Zhang G
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Chen, Zhengshan
AU  - Chen Z
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Liu, Yujiao
AU  - Liu Y
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Fang, Ting
AU  - Fang T
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Li, Jianmin
AU  - Li J
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Banadyga, Logan
AU  - Banadyga L
AD  - Special Pathogens Program, National Microbiology Laboratory, Public Health Agency 
      of Canada, Winnipeg, Canada.
FAU - He, Shihua
AU  - He S
AD  - Special Pathogens Program, National Microbiology Laboratory, Public Health Agency 
      of Canada, Winnipeg, Canada.
FAU - Yu, Changming
AU  - Yu C
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
FAU - Qiu, Xiangguo
AU  - Qiu X
AD  - Special Pathogens Program, National Microbiology Laboratory, Public Health Agency 
      of Canada, Winnipeg, Canada.
FAU - Chen, Wei
AU  - Chen W
AD  - Laboratory of Vaccine and Antibody Engineering, Beijing Institute of 
      Biotechnology, Beijing, China.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - MAbs
JT  - mAbs
JID - 101479829
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Ebola Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*immunology
MH  - Antibodies, Neutralizing/*immunology
MH  - Antibodies, Viral/*immunology
MH  - Ebola Vaccines/*immunology
MH  - Ebolavirus/*immunology
MH  - Female
MH  - Hemorrhagic Fever, Ebola/immunology/prevention & control
MH  - Humans
MH  - Male
MH  - Mice
PMC - PMC7153831
OTO - NOTNLM
OT  - Cross-reactivity
OT  - Ebola virus
OT  - epitope
OT  - memory B cell
OT  - monoclonal antibodies
OT  - neutralization
OT  - protection
EDAT- 2020/03/28 06:00
MHDA- 2021/02/13 06:00
PMCR- 2020/03/26
CRDT- 2020/03/28 06:00
PHST- 2020/03/28 06:00 [entrez]
PHST- 2020/03/28 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
PHST- 2020/03/26 00:00 [pmc-release]
AID - 1742457 [pii]
AID - 10.1080/19420862.2020.1742457 [doi]
PST - ppublish
SO  - MAbs. 2020 Jan-Dec;12(1):1742457. doi: 10.1080/19420862.2020.1742457.